Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 609

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 609
---
        |     | $           | 52,500 |     | $            |  3,832 |     | $              | — |     | $            | — |     | $            | — |     | $         | 56,332 |
| Scott Dylla, Ph.D.          |     | $           | 45,000 |     | $            |  3,832 |     | $              | — |     | $            | — |     | $            | — |     | $         | 48,832 |
| Marion R. Foote             |     | $           | 55,000 |     | $            |  3,832 |     | $              | — |     | $            | — |     | $            | — |     | $         | 58,832 |
| Shawn Iadonato, Ph.D.(4)    |     | $           | 48,750 |     | $            | 22,919 |     | $              | — |     | $            | — |     | $            | — |     | $         | 71,669 |
| Richard Peters, M.D., Ph.D. |     | $           | 65,000 |     | $            |  3,832 |     | $              | — |     | $            | — |     | $            | — |     | $         | 68,832 |

| (1) | Amounts represent cash compensation for services rendered as a director during 2024. |

| (2) | The amounts reported represent the aggregate grant date fair value of stock options granted to the non-employee directors during fiscal year 2024, calculated in accordance with FASB ASC Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in Note 2 to Kineta’s financial statements included in Kineta’s 2024 Annual Report on Form 10-K. The amounts reported in this column reflect the accounting cost for the stock options and does not correspond to the actual economic value that may be received upon exercise of the stock options or any sale of any of the underlying shares of common stock. |

| (3) | The following table shows the number of outstanding stock options held by Kineta’s directors as of December 31, 2024: |

|